🇺🇸 Insulin glargine, 100 U/ml in United States

12 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Renal Failure — 2 reports (16.67%)
  2. Rhabdomyolysis — 2 reports (16.67%)
  3. Acute Respiratory Distress Syndrome — 1 report (8.33%)
  4. Compartment Syndrome — 1 report (8.33%)
  5. Embolism — 1 report (8.33%)
  6. Encephalopathy — 1 report (8.33%)
  7. Malaise — 1 report (8.33%)
  8. Osteonecrosis — 1 report (8.33%)
  9. Pancreatitis Necrotising — 1 report (8.33%)
  10. Peripheral Artery Occlusion — 1 report (8.33%)

Source database →

Other Diabetes approved in United States

Frequently asked questions

Is Insulin glargine, 100 U/ml approved in United States?

Insulin glargine, 100 U/ml does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Insulin glargine, 100 U/ml in United States?

Sanofi is the originator. The local marketing authorisation holder may differ — check the official source linked above.